• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Hannon Armstrong Appoints Former EXIM Chairman Kimberly A. Reed and CEO Jeffrey A. Lipson to Board of Directors

    3/1/23 8:30:00 AM ET
    $HASI
    $MNTS
    $TAK
    Finance/Investors Services
    Finance
    Military/Government/Technical
    Industrials
    Get the next $HASI alert in real time by email

    Hannon Armstrong Sustainable Infrastructure Capital, Inc. ("Hannon Armstrong" or "HASI") (NYSE:HASI), a leading investor in climate solutions, today announced the appointment of Kimberly A. Reed and Jeffrey A. Lipson to its Board of Directors, effective March 1, 2023.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230301005447/en/

    Kimberly A. Reed (Photo: Business Wire)

    Kimberly A. Reed (Photo: Business Wire)

    In connection with these elections, the Board of Directors will consist of 11 members, 9 of whom are independent members. The Board appointed Ms. Reed to serve as a member of the Audit Committee and the Finance and Risk Committee.

    "We are delighted to add Kimberly Reed's talent and perspective to our Board as HASI continues to grow in ambition and scale," said Jeffrey W. Eckel, HASI Executive Chair. "Kimberly's demonstrated leadership in resurrecting and running the U.S. Export-Import Bank adds important government and regulatory experience and global connectivity to our Board, as well as another seasoned financial services voice."

    Ms. Reed said, "Hannon Armstrong Sustainable Infrastructure Capital, Inc.— the very first U.S. public company to focus solely on investments in energy efficiency, renewable energy, and other sustainable infrastructure markets and now with more than $9 billion in managed assets — plays a unique and pivotal role in the renewables firmament. HASI is led by a team that collectively brings unparalleled longevity in this rapidly evolving space, and I am confident that my experience leading major public agencies and engaging with diverse businesses across the United States will complement this superior team and the company's already substantive Board of Directors."

    Ms. Reed currently serves on the Board of Directors of Takeda Pharmaceutical Company Limited (NYSE:TAK) and Momentus Inc. (NASDAQ:MNTS) and is a distinguished fellow with the Council on Competitiveness.

    Ms. Reed served as the first woman chairman of the Board of Directors, president and chief executive officer of the Export-Import Bank of the United States (EXIM) — the nation's official $135 billion export credit agency — from 2019 to 2021 after being confirmed by the U.S. Senate with overwhelming bipartisan support. As EXIM chairman, she worked to help U.S. companies — including those in the renewable and clean energy and transformational technology sectors —succeed in the competitive global marketplace. Earlier in her career, Ms. Reed was president of the International Food Information Council Foundation, where she worked with multi-national food and agribusiness companies on nutrition, health, and sustainability issues; senior advisor to U.S. Treasury Secretaries Henry Paulson and John Snow; chief executive officer of the Community Development Financial Institutions Fund (CDFI Fund); and counsel to three committees of the U.S. Congress, where she conducted oversight and investigations.

    She also currently serves on the American Swiss Foundation Board of Directors, Hudson Institute's Alexander Hamilton Commission on Securing America's National Security Innovation Base, Krach Institute for Tech Diplomacy at Purdue Advisory Council and Indiana University School of Public Health-Bloomington Dean's Alliance.

    Recognized as one of the "100 Women Leaders in STEM," Ms. Reed received the U.S. Department of Defense's highest civilian award — the Medal for Distinguished Public Service — and is a Council on Foreign Relations life member and National Association of Corporate Directors (NACD) Certified Director. She holds a Juris Doctor from West Virginia University College of Law and a Bachelor of Science in biology and a Bachelor of Arts in government from West Virginia Wesleyan College.

    "We also welcome our new CEO, Jeff Lipson, on the Board," Mr. Eckel added. As previously announced, Jeffrey A. Lipson has transitioned to the role of president and chief executive officer of HASI effective today. Mr. Lipson served as both chief operating officer and chief financial officer of HASI from January 2021 to February 2023, and chief financial officer from January 2019 to December 2020.

    About Hannon Armstrong

    Hannon Armstrong (NYSE:HASI) is the first U.S. public company solely dedicated to investments in climate solutions, providing capital to assets developed by leading companies in energy efficiency, renewable energy, and other sustainable infrastructure markets. With more than $9 billion in managed assets, our core purpose is to make climate positive investments with superior risk-adjusted returns. For more information, please visit hannonarmstrong.com or follow us on Twitter and LinkedIn.

    Forward-Looking Statements

    Some of the information contained in this press release is forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended that are subject to risks and uncertainties. For these statements, we claim the protections of the safe harbor for forward-looking statements contained in such Sections. These forward-looking statements include information about possible or assumed future results of our business, financial condition, liquidity, results of operations, plans and objectives. When we use the words "believe," "expect," "anticipate," "estimate," "plan," "continue," "intend," "should," "may" or similar expressions, we intend to identify forward-looking statements.

    Forward-looking statements are subject to significant risks and uncertainties. Investors are cautioned against placing undue reliance on such statements. Actual results may differ materially from those set forth in the forward-looking statements. Factors that could cause actual results to differ materially from those described in the forward-looking statements include those discussed under the caption "Risk Factors" included in our most recent Annual Report on Form 10-K as well as in other periodic reports that we file with the U.S. Securities and Exchange Commission

    Forward-looking statements are based on beliefs, assumptions and expectations as of the date of this press release. We disclaim any obligation to publicly release the results of any revisions to these forward-looking statements reflecting new estimates, events or circumstances after the date of this press release.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20230301005447/en/

    Get the next $HASI alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HASI
    $MNTS
    $TAK

    CompanyDatePrice TargetRatingAnalyst
    Takeda Pharmaceutical Company Limited
    $TAK
    4/2/2025Equal-Weight → Overweight
    Morgan Stanley
    HA Sustainable Infrastructure Capital Inc.
    $HASI
    2/27/2025$33.00Overweight
    Wells Fargo
    HA Sustainable Infrastructure Capital Inc.
    $HASI
    2/6/2025$40.00Buy
    Truist
    HA Sustainable Infrastructure Capital Inc.
    $HASI
    1/8/2025$36.00Neutral → Buy
    Citigroup
    HA Sustainable Infrastructure Capital Inc.
    $HASI
    11/25/2024$40.00Buy
    BofA Securities
    HA Sustainable Infrastructure Capital Inc.
    $HASI
    9/4/2024$39.00Buy
    Jefferies
    HA Sustainable Infrastructure Capital Inc.
    $HASI
    9/3/2024$41.00Outperform
    RBC Capital Mkts
    HA Sustainable Infrastructure Capital Inc.
    $HASI
    11/28/2023$26.00Neutral
    Goldman
    More analyst ratings

    $HASI
    $MNTS
    $TAK
    SEC Filings

    View All

    SEC Form S-1 filed by Momentus Inc.

    S-1 - Momentus Inc. (0001781162) (Filer)

    10/24/25 4:50:09 PM ET
    $MNTS
    Military/Government/Technical
    Industrials

    SEC Form 424B5 filed by Momentus Inc.

    424B5 - Momentus Inc. (0001781162) (Filer)

    10/20/25 5:27:30 PM ET
    $MNTS
    Military/Government/Technical
    Industrials

    Amendment: SEC Form S-1/A filed by Momentus Inc.

    S-1/A - Momentus Inc. (0001781162) (Filer)

    10/17/25 5:18:42 PM ET
    $MNTS
    Military/Government/Technical
    Industrials

    $HASI
    $MNTS
    $TAK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Takeda Pharma upgraded by Morgan Stanley

    Morgan Stanley upgraded Takeda Pharma from Equal-Weight to Overweight

    4/2/25 8:46:19 AM ET
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wells Fargo initiated coverage on Hannon Armstrong Sust. Infr. with a new price target

    Wells Fargo initiated coverage of Hannon Armstrong Sust. Infr. with a rating of Overweight and set a new price target of $33.00

    2/27/25 6:22:05 AM ET
    $HASI
    Finance/Investors Services
    Finance

    Truist initiated coverage on Hannon Armstrong Sust. Infr. with a new price target

    Truist initiated coverage of Hannon Armstrong Sust. Infr. with a rating of Buy and set a new price target of $40.00

    2/6/25 7:06:39 AM ET
    $HASI
    Finance/Investors Services
    Finance

    $HASI
    $MNTS
    $TAK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Pangburn Marc T. bought $100,485 worth of shares (3,500 units at $28.71), increasing direct ownership by 7% to 56,791 units (SEC Form 4)

    4 - HA Sustainable Infrastructure Capital, Inc. (0001561894) (Issuer)

    11/12/24 4:49:08 PM ET
    $HASI
    Finance/Investors Services
    Finance

    Armbrister Clarence D bought $10,076 worth of shares (420 units at $23.99) (SEC Form 4)

    4 - Hannon Armstrong Sustainable Infrastructure Capital, Inc. (0001561894) (Issuer)

    11/20/23 4:12:23 PM ET
    $HASI
    Finance/Investors Services
    Finance

    $HASI
    $MNTS
    $TAK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Operating Officer Gopalakrishnan Nitya

    4 - HA Sustainable Infrastructure Capital, Inc. (0001561894) (Issuer)

    9/16/25 4:17:20 PM ET
    $HASI
    Finance/Investors Services
    Finance

    SEC Form 3 filed by new insider Gopalakrishnan Nitya

    3 - HA Sustainable Infrastructure Capital, Inc. (0001561894) (Issuer)

    9/11/25 4:15:58 PM ET
    $HASI
    Finance/Investors Services
    Finance

    SEC Form 4 filed by CFO Ensler Lon

    4 - Momentus Inc. (0001781162) (Issuer)

    9/10/25 4:08:05 PM ET
    $MNTS
    Military/Government/Technical
    Industrials

    $HASI
    $MNTS
    $TAK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Innovent Biologics Announces Global Strategic Partnership with Takeda to Bring Innovent's Next Gen IO Backbone Therapy and ADC Molecules to the Global Market

    The collaboration combines Innovent's proven immuno-oncology ("IO") and antibody-drug conjugate ("ADC") R&D capability and Takeda's experience in global oncology drug development to accelerate Innovent's two late-stage investigational medicines worldwide, and Takeda receives an option for an early-stage program.Innovent and Takeda will co-develop the IO backbone therapy IBI363 (PD-1/IL-2α-bias) globally and co-commercialize it in the U.S., where Takeda will lead the co-development and co-commercialization efforts under joint governance and aligned development plan; Takeda will receive exclusive commercialization rights outside Greater China and the U.S.Innovent will grant Takeda exclusive ri

    10/21/25 8:25:00 PM ET
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Takeda Enters Global Strategic Partnership with Innovent Biologics to Bolster Oncology Pipeline with Next-Generation Investigational Medicines for Treatment of Solid Tumors

    Takeda to Receive Rights to Two Next-Generation Late-Stage Investigational Medicines, Worldwide Outside of Greater China, and an Exclusive Option to License Global Rights to an Early-Stage Program Takeda to Lead IBI363 Global Co-Development and U.S. Co-Commercialization and Will Have Exclusive Commercialization Rights Outside the U.S. and Greater China; IBI363 is a Late-Stage Bispecific Antibody Fusion Protein Being Evaluated in Non-Small Cell Lung and Colorectal Cancers, with Potential in Additional Solid Tumor Types Takeda to Receive Exclusive Rights for IBI343 Outside of Greater China; IBI343 is a Late-Stage Antibody-Drug Conjugate Being Evaluated in Gastric and Pancreatic Cancers

    10/21/25 8:25:00 PM ET
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HASI Announces Third Quarter 2025 Earnings Release Date and Conference Call

    HA Sustainable Infrastructure Capital, Inc. ("HASI," "We", "Our," or the "Company") (NYSE:HASI), a leading investor in sustainable infrastructure assets, today announced that the Company will release its third quarter 2025 results after market close on Thursday, November 6, 2025, to be followed by a conference call at 5:00 p.m. (Eastern Time). The conference call can be accessed live over the phone by dialing 1-877-407-0890 (Toll-Free) or +1-201-389-0918 (toll). Participants should inform the operator they would like to join the "HASI Third Quarter 2025 Results" call. The conference call will also be accessible as an audio webcast with slides on our website. A replay after the event will

    10/16/25 7:00:00 AM ET
    $HASI
    Finance/Investors Services
    Finance

    $HASI
    $MNTS
    $TAK
    Leadership Updates

    Live Leadership Updates

    View All

    Takeda Appoints Rhonda Pacheco President of the U.S. Business Unit

    − Rhonda Pacheco to Succeed Julie Kim, Who Was Appointed to Be Takeda's Next CEO Takeda ((TAK) today announced that Rhonda Pacheco, most recently group vice president of U.S. Cardiometabolic Health at Eli Lilly, will join Takeda, effective September 29, as president of Takeda's U.S. Business Unit and will be a member of the Takeda Executive Team. Pacheco will succeed Julie Kim, who was appointed by the Takeda Board of Directors to succeed Christophe Weber as president and Chief Executive Officer (CEO) of Takeda in June 2026. With Pacheco's appointment, Kim will focus on preparing for the CEO transition, which includes serving as interim head of the Global Portfolio Division. This press r

    9/11/25 8:45:00 AM ET
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HASI Welcomes Nitya Gopalakrishnan as Chief Operating Officer

    HA Sustainable Infrastructure Capital, Inc. ("HASI," "We," "Our," or the "Company") (NYSE:HASI), a leading investor in sustainable infrastructure assets, today announced the appointment of Nitya Gopalakrishnan as Executive Vice President and Chief Operating Officer. In this role, Ms. Gopalakrishnan will lead the company's technology, data strategy, and operational strategy as HASI continues to scale its investment platform and internal infrastructure to support expected continued growth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250714595142/en/Nitya Gopalakrishnan Before joining HASI, Ms. Gopalakrishnan spent 25 years at B

    7/14/25 4:15:00 PM ET
    $HASI
    Finance/Investors Services
    Finance

    Shoals Technologies Group, Inc. Appoints Industry Veteran, Bobbie L. King, Jr., as Chief Legal Officer

    PORTLAND, Tenn., June 16, 2025 (GLOBE NEWSWIRE) -- Shoals Technologies Group, Inc. ("Shoals"), a leading provider of electrical balance of system solutions for the global energy transition market, announced today that it has further strengthened its executive team with the addition of Bobbie L. King, Jr. as Chief Legal Officer and Corporate Secretary to drive its legal strategy and support sustainable growth. Mr. King brings over 15 years of legal and leadership experience in the clean infrastructure industry. He joins Shoals from HA Sustainable Infrastructure Capital, Inc. (NYSE:HASI), where he served as Senior Vice President & Deputy Chief Legal Officer. Mr. King has also held senior le

    6/16/25 4:35:00 PM ET
    $HASI
    $SHLS
    Finance/Investors Services
    Finance
    Semiconductors
    Technology

    $HASI
    $MNTS
    $TAK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Momentus Inc.

    SC 13G/A - Momentus Inc. (0001781162) (Subject)

    11/14/24 5:14:58 PM ET
    $MNTS
    Military/Government/Technical
    Industrials

    Amendment: SEC Form SC 13G/A filed by Momentus Inc.

    SC 13G/A - Momentus Inc. (0001781162) (Subject)

    11/14/24 5:14:34 PM ET
    $MNTS
    Military/Government/Technical
    Industrials

    Amendment: SEC Form SC 13G/A filed by HA Sustainable Infrastructure Capital Inc.

    SC 13G/A - HA Sustainable Infrastructure Capital, Inc. (0001561894) (Subject)

    11/8/24 10:52:39 AM ET
    $HASI
    Finance/Investors Services
    Finance

    $HASI
    $MNTS
    $TAK
    Financials

    Live finance-specific insights

    View All

    Innovent Biologics Announces Global Strategic Partnership with Takeda to Bring Innovent's Next Gen IO Backbone Therapy and ADC Molecules to the Global Market

    The collaboration combines Innovent's proven immuno-oncology ("IO") and antibody-drug conjugate ("ADC") R&D capability and Takeda's experience in global oncology drug development to accelerate Innovent's two late-stage investigational medicines worldwide, and Takeda receives an option for an early-stage program.Innovent and Takeda will co-develop the IO backbone therapy IBI363 (PD-1/IL-2α-bias) globally and co-commercialize it in the U.S., where Takeda will lead the co-development and co-commercialization efforts under joint governance and aligned development plan; Takeda will receive exclusive commercialization rights outside Greater China and the U.S.Innovent will grant Takeda exclusive ri

    10/21/25 8:25:00 PM ET
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HASI Announces Third Quarter 2025 Earnings Release Date and Conference Call

    HA Sustainable Infrastructure Capital, Inc. ("HASI," "We", "Our," or the "Company") (NYSE:HASI), a leading investor in sustainable infrastructure assets, today announced that the Company will release its third quarter 2025 results after market close on Thursday, November 6, 2025, to be followed by a conference call at 5:00 p.m. (Eastern Time). The conference call can be accessed live over the phone by dialing 1-877-407-0890 (Toll-Free) or +1-201-389-0918 (toll). Participants should inform the operator they would like to join the "HASI Third Quarter 2025 Results" call. The conference call will also be accessible as an audio webcast with slides on our website. A replay after the event will

    10/16/25 7:00:00 AM ET
    $HASI
    Finance/Investors Services
    Finance

    Takeda Presents Orexin Data from Landmark Oveporexton (TAK-861) Phase 3 Program in Narcolepsy Type 1 at World Sleep 2025

    – Takeda is the Leader in Orexin Science and is on Track to Submit Global Regulatory Applications Starting in Fiscal Year 2025 – Four Orexin Oral Presentations from Phase 3 Pivotal Studies Highlight Statistically Significant and Clinically Meaningful Improvement in Narcolepsy Type 1 Symptoms Demonstrating the Potential for a New Era of Care – Oveporexton was Generally Well-Tolerated with Safety Profile Consistent with Previous Clinical Studies Takeda ((TAK) will present data from two global Phase 3 double-blind, placebo-controlled studies of oveporexton (TAK-861)1, a potential first-in-class investigational oral orexin receptor 2 (OX2R)-selective agonist in narcolepsy type 1 (NT1), du

    9/8/25 3:00:00 AM ET
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care